根据国家药品监督管理局药品审评中心网站公示,12月以来,已有五款创新药纳入或拟纳入突破性治疗品种名单,覆盖白癜风、肺癌、前列腺癌等多个治疗领域。其中,有2款创新药已经纳入突破性治疗品种名单,包括海南德镁医药科技有限责任公司的磷酸泊沃昔替尼片,拟用于成人患者非节段型白癜风的治疗;苏州泽璟生物制药股份有限公司的注射用ZG006,单药治疗既往至少经含铂方案治疗后复发或进展的DLL3阳性(≥50%的肿瘤...
Source Link根据国家药品监督管理局药品审评中心网站公示,12月以来,已有五款创新药纳入或拟纳入突破性治疗品种名单,覆盖白癜风、肺癌、前列腺癌等多个治疗领域。其中,有2款创新药已经纳入突破性治疗品种名单,包括海南德镁医药科技有限责任公司的磷酸泊沃昔替尼片,拟用于成人患者非节段型白癜风的治疗;苏州泽璟生物制药股份有限公司的注射用ZG006,单药治疗既往至少经含铂方案治疗后复发或进展的DLL3阳性(≥50%的肿瘤...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.